Is Kymera (KYMR) the Best Performing American Stock in June 2026?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 10 Best Performing American Stocks in June 2026.

On June 30, 2026, BofA raised the firm’s price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) to $125 from $110 and kept a Buy rating on the shares. BofA adjusted its launch timing expectations after Kymera said enrollment in the phase 2b BROADEN trial evaluating KT-621 in atopic dermatitis was completed approximately 6 months ahead of schedule. BofA currently models $6B in nominal peak sales for KT-621 in AD.

On June 29, B. Riley raised the firm’s price target on Kymera Therapeutics to $155 from $117 and kept a Buy rating on the shares. B. Riley said the company unexpectedly completed BROADEN2 Phase 2b enrollment in moderate-to-severe atopic dermatitis six months early. The firm noted that Kymera moved the readout to year-end 2026 from mid-2027 and is advancing the planned Phase 3 initiation to mid-2027. B. Riley said it is a buyer of the stock on the “encouraging update,” calling KT-621 Kymera’s “single most important value driver.”

Pixabay/Public Domain

Also on June 29, Truist analyst Srikripa Devarakonda raised the firm’s price target on Kymera Therapeutics to $136 from $116 and kept a Buy rating on the shares. Devarakonda viewed Kymera positively following accelerated development timelines for KT-621, with clinician feedback pointing to strong interest in an oral therapy with Dupixent-like efficacy and high enthusiasm among dermatology key opinion leaders.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.